Web Desc
Advances in Cancer Immunotherapy
Scientific Organizers: Antoni Ribas, W. Nicholas Haining and Priti Hegde
Date: March 22 - 26, 2020
Location: Fairmont Chateau Whistler, Whistler, BC, Canada
Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to generous support from an anonymous donor.

Sponsored by BioLegend, Inc., Compass Therapeutics, Gilead Sciences, Inc., Genentech, Inc., Incyte Corporation, MorphoSys AG and Surface Oncology
Summary of Meeting:
Cancer immunotherapy by blocking immune inhibitory checkpoints or engineering T cells for adoptive cell transfer is providing an unprecedented level of long-term antitumor activity in patients with several metastatic cancers. However, the majority of patients with advanced cancers still do not experience sustained clinical benefit from immunotherapy. Understanding the mechanistic basis of response and resistance to these therapies and how therapeutic approaches could best be combined will be essential to continue progress. The largest human experiment is currently being conducted with over 1,000 agents and combinations. Understanding the results to date and determining what is working and what combinations are not working will be important to refine our understanding of immunity in patients with cancer. Questions that remain unanswered include: What is the rationale for the multiple immuno-oncology (IO) combinations being tested in the clinic, how do cancers adapt and resist T cell attack, and can we better understand the tumor microenvironment, thus paving the way for new approaches to cancer therapy. New analyses of patient-derived samples provide information on adaptive and genetic resistance mechanisms to immunotherapy. The conference program will include sessions which cover topics such as new analysis techniques, methodologies, and how to integrate high throughput data to provide a more comprehensive understanding of cancer and the immune system. Participants will leave the conference with an understanding of how the advancement of cancer biology will be influenced by a better comprehension of tumor immunology.
DEADLINES:
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Deadline: November 19 2019 details
Discounted Abstract Deadline: November 19 2019 details & pricing
Abstract Deadline: December 17 2019 details & pricing
Discounted Registration Deadline: January 22 2020 details & pricing


Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.


Keystone Symposia thanks our Sponsor for generously supporting this meeting:
BioLegend, Inc.Compass TherapeuticsGenentech, Inc.Gilead Sciences, Inc.Incyte CorporationMorphoSys AGSurface Oncology
We gratefully acknowledge additional support from these exhibitors at this conference:
10x GenomicsMyriad-RBM
We gratefully acknowledge additional support for this conference from:
AdipoGen Life SciencesAgilentAmerican Association for Cancer Research (AACR)MacroGenics, Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Genentech, Inc.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found